Safety of Prohemostatic Interventions

 

 Buy Article Permissions and Reprints

Abstract

Pharmacological prohemostatic agents may be useful adjunctive treatment options in patients with severe blood loss. The efficacy of these interventions has been established in a variety of clinical situations. However, the procoagulant effect of these interventions may tip the balance toward a higher risk of thrombotic complications. Several studies have shown that some prohemostatic interventions may indeed increase the risk of arterial and venous thromboembolism, although these complications are relatively rare. When considering the use of adjunctive prohemostatic agents to prevent or treat excessive blood loss, the risk of thrombotic complications should be taken into account.

• References

• 1 Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356 (22) 2301-2311
  CrossrefPubMedGoogle Scholar
• 2 Levi M. Critical bleeding in surgery: conventional therapy and new prospects. Minerva Anestesiol 2004; 70 (5) 267-271
  PubMedGoogle Scholar
• 3 Levi M, Vink R, de Jonge E. Prevention and treatment of bleeding by pro-hemostatic treatment strategies. Wien Med Wochenschr 2003; 153 (19-20) 421-425
  CrossrefPubMedGoogle Scholar
• 4 Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ ; American College of Chest Physicians. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 110S-112S
  CrossrefPubMedGoogle Scholar
• 5 Levi MM, Eerenberg E, Löwenberg E, Kamphuisen PW. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010; 68 (2) 68-76
  PubMedGoogle Scholar
• 6 Levi M, Eerenberg E, Kamphuisen PW. Periprocedural reversal and bridging of anticoagulant treatment. Neth J Med 2011; 69 (6) 268-273
  PubMedGoogle Scholar
• 7 Caplan SN, Berkman EM. Letter: Protamine sulfate and fish allergy. N Engl J Med 1976; 295 (3) 172
  PubMedGoogle Scholar
• 8 Fearn SJ, Parry AD, Picton AJ, Mortimer AJ, McCollum CN. Should heparin be reversed after carotid endarterectomy? A randomised prospective trial. Eur J Vasc Endovasc Surg 1997; 13 (4) 394-397
  CrossrefPubMedGoogle Scholar
• 9 Mauney MC, Buchanan SA, Lawrence WA , et al. Stroke rate is markedly reduced after carotid endarterectomy by avoidance of protamine. J Vasc Surg 1995; 22 (3) 264-269, discussion 269–270
  CrossrefPubMedGoogle Scholar
• 10 Dellagrammaticas D, Lewis SC, Gough MJ ; GALA Trial Collaborators. Is heparin reversal with protamine after carotid endarterectomy dangerous?. Eur J Vasc Endovasc Surg 2008; 36 (1) 41-44
  CrossrefPubMedGoogle Scholar
• 11 Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4 (9) 1853-1863
  CrossrefPubMedGoogle Scholar
• 12 Baglin T. Management of warfarin (coumarin) overdose. Blood Rev 1998; 12 (2) 91-98
  CrossrefPubMedGoogle Scholar
• 13 Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 1998; 158 (19) 2136-2140
  CrossrefPubMedGoogle Scholar
• 14 Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001; 115 (1) 145-149
  CrossrefPubMedGoogle Scholar
• 15 Crowther MA, Douketis JD, Schnurr T , et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 137 (4) 251-254
  CrossrefPubMedGoogle Scholar
• 16 Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 163 (20) 2469-2473
  CrossrefPubMedGoogle Scholar
• 17 Martin JC. Anaphylactoid reactions and vitamin K. Med J Aust 1991; 155 (11-12) 851
  PubMedGoogle Scholar
• 18 Fiore LD, Scola MA, Cantillon CE, Brophy MT. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001; 11 (2) 175-183
  CrossrefPubMedGoogle Scholar
• 19 Dentali F, Ageno W. Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review. Haematologica 2004; 89 (7) 857-862
  PubMedGoogle Scholar
• 20 Aguilar MI, Hart RG, Kase CS , et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007; 82 (1) 82-92
  CrossrefPubMedGoogle Scholar
• 21 Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77 (3) 477-480
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124 (14) 1573-1579
  CrossrefPubMedGoogle Scholar
• 23 Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83 (2) 137-143
  CrossrefPubMedGoogle Scholar
• 24 Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33 (4) 883-890
  CrossrefPubMedGoogle Scholar
• 25 Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985; 103 (2) 228-239
  CrossrefPubMedGoogle Scholar
• 26 Löwenberg EC, Meijers JC, Levi M. Platelet-vessel wall interaction in health and disease. Neth J Med 2010; 68 (6) 242-251
  PubMedGoogle Scholar
• 27 McLeod BC. Myocardial infarction in a blood donor after administration of desmopressin. Lancet 1990; 336 (8723) 1137-1138
  PubMedGoogle Scholar
• 28 Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6 (1) 11-14
  CrossrefPubMedGoogle Scholar
• 29 Miesbach W, Krekeler S, Dück O , et al. Clinical assessment of efficacy and safety of DDAVP. Hamostaseologie 2010; 30 (Suppl. 01) S172-S175
  PubMedGoogle Scholar
• 30 Perry D, Berntorp E, Tait C , et al. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations. Haemophilia 2010; 16 (1) 80-89
  PubMedGoogle Scholar
• 31 Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2 (10) 1700-1708
  CrossrefPubMedGoogle Scholar
• 32 Valentino LA. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2010; 16 (2) 263-271
  CrossrefPubMedGoogle Scholar
• 33 Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 01) S107-S111
  CrossrefPubMedGoogle Scholar
• 34 Friederich PW, Levi M, Bauer KA , et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001; 103 (21) 2555-2559
  CrossrefPubMedGoogle Scholar
• 35 Hoffman M, Monroe III DM, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 01) S61-S65
  PubMedGoogle Scholar
• 36 Mayer SA, Brun N, Broderick J , et al. Recombinant factor via for acute intracerebral hemorrhage. Proceedings 5th World Stroke Congress 2004;Vancouver, 26 June 2004
  PubMedGoogle Scholar
• 37 O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295 (3) 293-298
  CrossrefPubMedGoogle Scholar
• 38 Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363 (19) 1791-1800
  CrossrefPubMedGoogle Scholar
• 39 Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339 (4) 245-253
  CrossrefPubMedGoogle Scholar
• 40 van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99 (5) 788-796, discussion 796–797
  PubMedGoogle Scholar
• 41 Levi M, Cromheecke ME, de Jonge E , et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354 (9194) 1940-1947
  CrossrefPubMedGoogle Scholar
• 42 Fremes SE, Wong BI, Lee E , et al. Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994; 58 (6) 1580-1588
  CrossrefPubMedGoogle Scholar
• 43 Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002; 62 (15) 2193-2211
  CrossrefPubMedGoogle Scholar
• 44 Mangano DT, Tudor IC, Dietzel C ; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354 (4) 353-365
  CrossrefPubMedGoogle Scholar
• 45 Hiatt WR. Observational studies of drug safety—aprotinin and the absence of transparency. N Engl J Med 2006; 355 (21) 2171-2173
  CrossrefPubMedGoogle Scholar
• 46 Fergusson DA, Hébert PC, Mazer CD , et al; BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358 (22) 2319-2331
  CrossrefPubMedGoogle Scholar
• 47 Shakur H, Roberts I, Bautista R , et al; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376 (9734) 23-32
  CrossrefPubMedGoogle Scholar
• 48 Ubbink DT, Vermeulen H, Knops AM , et al. Implementation of evidence-based practice: outside the box, throughout the hospital. Neth J Med 2011; 69 (2) 87-94
  PubMedGoogle Scholar